Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 1155-1158

  Oremek, G M ^a,b   Rutner, F ^a   Sapoutzis, N ^a   Sauer Eppel, H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Diabetic nephropathy; TU M2 PK

Indexed keywords

GLUCOSE; ISOENZYME; PYRUVATE KINASE; TUMOR MARKER;

ANALYTICAL PARAMETERS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ISOENZYMES; PYRUVATE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0038575910     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Board M, Humm S and Newsholme EA.: Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 265: 503-509, 1990.
2. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H and Friis R: A double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Critical reviews in Oncogenesis 3: 91-115, 1992.
3. Oremek, GM, Teigelkamp S, Kramer W, Eigenbrodt E and Usadel K-H: The pyruvate kinase isoenzyme Tumor M2 (TU M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 19: 2599-2602, 1999.
4. Schwartz MK: Enzymes used in predicting high risk to colon cancer. Clin Biochem 23: 395-398, 1990.
5. Mazurek S, Scheefers-Borchel U, Scheefers H, Michel A, Basenau D, Fischer G, Dahlmann N, Laumen R and Eigenbrodt E: Die Bedeutung der Pyruvatkinase in der Onkologie. Notabene Medici 3: 97-104, 1993.
6. Eigenbrodt E, Basenau D, Holzhusen S, Mazurek S and Fischer, G: Quantification of tumor type M2 pyruvate kinase (TU M2-PK) in human carcinomas. Anticancer Res 17: 3153-3156, 1997.
7. Oremek GM, Eigenbrodt E, Rädle J, Zeuzem St and Seiffert UB: Value of the serum levels of the tumor marker TU M2-PK in pancreatic cancer. Anticancer Res 17: 3031-3034, 1997.
8. Cerwenka H, Aigner R, Bacher H, Werkgartner G, El-Shabrawi A, Quehenberger F and Mischinger HJ: TU M2-PK, Ca 19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 19: 849-852, 1999.
9. Wechsel HW, Petri E, Feil G, Nelde H-J and Bichler K-H: Nierenzellkarzinom - Histologische untersuchungen zur expression der inaktiven form der pyruvatkinase. Urologe 38: 583-585, 1999.
10. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E and Usadel K-H: The pyruvate kinase isoenzyme Tumor M2 (TU M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 19: 2599-2602, 1999.
11. Wechsel HW, Petri E, Bichler K-H and Feil G: Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (TU M2-PK). Anticancer Res 19: 2583-2590, 1999.
12. Wechsel HW, Feil G, Lahme S, Loeser W and Bichler K-H: Die Plasmainaktive form der Pyruvatkinase (TU M2-PK) beim Nierenzellkarzinom: ein geeigneter Tumormarker? Akt Urol 30: 249-253, 1999.
13. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D and Loening DA: Tumor M2-Pyruvatkinase beim Nierenzellkarzinom. Untersuchungen in Plasma von Patienten. Urologe 39: 554-556, 2000.
14. Hugo F, Fischer G and Eigenbrodt E: Quantitative detection of Tumor M2-Pk in serum and plasma. Anticancer Res 19: 2753-2758, 1999.